Avacopan
Chemical compound / From Wikipedia, the free encyclopedia
Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis.[5][6][8] Avacopan is a complement 5a receptor antagonist[5] and a cytochrome P450 3A4 inhibitor.[5]
Clinical data | |
---|---|
Trade names | Tavneos |
Other names | CCX168 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a622023 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Complement C5a receptor antagonist |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
ECHA InfoCard | 100.351.344 |
Chemical and physical data | |
Formula | C33H35F4N3O2 |
Molar mass | 581.656 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects include nausea (feeling sick), headache, decrease in white blood cell count, upper respiratory tract (nose and throat) infection, diarrhea, vomiting, and nasopharyngitis (inflammation of the nose and throat).[6]
Avacopan was approved for medical use in Japan in September 2021,[7] and in the United States in October 2021.[5][8][9] It is the first orally-administered inhibitor of the complement C5a receptor approved by the US Food and Drug Administration (FDA).[8] The FDA considers it to be a first-in-class medication.[10]